507994116 07/05/2023

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8041256

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
QUOTIENT SCIENCES LIMITED	05/25/2023

RECEIVING PARTY DATA

Name:	EVECXIA THERAPEUTICS, INC.
Street Address:	2 DAVIS DRIVE
City:	RESEARCH TRIANGLE PARK
State/Country:	NORTH CAROLINA
Postal Code:	27709

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	17877699
PCT Number:	US2022038914

CORRESPONDENCE DATA

Fax Number: (919)419-0383

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 9194938000 Email: 9194938000 cblack@jwth.com

Correspondent Name: ARLES A. TAYLOR, JR.

Address Line 1: PO BOX 710

Address Line 4: MORRISVILLE, NORTH CAROLINA 27560

ATTORNEY DOCKET NUMBER:	3282/5/2; 3282/5 PCT
NAME OF SUBMITTER:	CONSTANCE BLACK
SIGNATURE:	/constance black/
DATE SIGNED:	07/05/2023

Total Attachments: 2

source=Executed_Assignment_Quotient_to_Evecxia_3282-5 PCT_3282-5-2#page1.tif source=Executed Assignment Quotient to Evecxia 3282-5 PCT 3282-5-2#page2.tif

PATENT 507994116 REEL: 064157 FRAME: 0315

Atty. Docket Nos.: 3282/5 PCT and 3282/5/2

ASSIGNMENT

WHEREAS, Quotient Sciences Limited, a corporation duly organized and existing under the laws of the United Kingdom, having its principal office and place of business at Trent House, Mere Way, Ruddington Fields Business Park, Ruddington, Nottingham, NG11 6JSM, United Kingdom (hereinafter "Assignor"), has acquired ownership in certain new and useful improvements in 5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORM (hereinafter "Invention") for which a PCT International Application was filed on July 29, 2022 as Serial No. PCT/US2022/038914, and a U.S. patent application was filed on July 29, 2022 as Application Serial No. 17/877,699 (hereinafter "Applications"), each claiming priority to U.S. Provisional Patent Application Serial No. 63/227,915 filed July 30, 2021.

AND, WHEREAS, Evecxia Therapeutics, Inc., a corporation duly organized and existing under the laws of the state of Delaware, having its principal office and place of business at 2 Davis Drive, Research Triangle Park, North Carolina 27709, United States (hereinafter "Assignee"), is desirous of Assignor's ownership interest therein.

NOW, THEREFORE, To Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor has sold and by these presents does hereby sell, assign, transfer and convey unto the Assignee, its successors and assigns, their entire right, title and interest in and to the Invention and Application, and in and to any and all U.S. and foreign patent applications filed on the Invention, and in and to any and all continuations, continuations-in-part, or divisions thereof, and in and to any and all Patents of the United States of America and all foreign countries or reissues thereof which may be granted therefor or thereon (hereinafter, "Patents"), for the full end of the term for which said Patents may be granted, together with their right to claim the priority of the Application in all countries in accordance with the Paris Convention, the Patent Cooperation Treaty, or other agreement or national law under which priority can be claimed, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made. It is expressly agreed by

Atty. Docket Nos.: 3282/5 PCT and 3282/5/2

Assignor and Assignee that this Assignment fully conveys and transfers from Assignor to Assignee the right to sue for any and all patent infringement occurring prior to the date of this Assignment.

Assignor hereby requests that said Patents be issued in accordance with this Assignment.

Assignor further covenants and agrees that, at the time of the execution and delivery of these presents, Assignor possesses the unencumbered right and authority to make this Assignment.

Assignor further covenants and agrees, and likewise bind their heirs, legal representatives and assigns, to promptly communicate to said Assignee or its representatives any facts known to him relating to the Invention, to testify and/or assist as requested by the Assignee in any interference or legal proceedings involving the Application, Patents, or Invention, including cooperating in any enforcement proceedings involving the Application, Patents, or Invention, to execute any additional papers which may be requested to confirm the right of the Assignee, its representatives, successors and assigns to secure patent or similar protection for the Invention in all countries and to vest in the Assignee complete title to the Invention and Patents, without further compensation, but at the expense of said Assignee, its successors, assigns and other legal representatives.

Executed this	25day of	20 <u></u> 3
	QUOTIENT SCIENCE	S LIMITED
	Not the same of th	
	NAME: WARE 148%	W
186432//	TITLE: (6)	
Witnessed	25/Wai 23	
Name K.HALL	Date	
CLD 550M	25 May 2023	
Name E.L. SISSING	Date	
6-6-010000000	* * * * * * * *	

-2 of 2-

PATENT REEL: 064157 FRAME: 0317

RECORDED: 07/05/2023